Abstract: 179 words Total word count: 2,895 words 2 ABSTRACT Heterotypic cell-cell adhesion and aggregation mediate vaso-occlusive events in patients with sickle cell disease (SCD). Although hydroxyurea (HU), an inducer of fetal hemoglobin, is the main therapy for treatment of SCD, it is unclear whether it has immediate benefits in acute vaso-occlusive events in SCD patients. Using real-time fluorescence intravital microscopy, we demonstrated that short-term co-administration of HU and Akti XII, an AKT2 inhibitor, efficiently reduced neutrophil adhesion and platelet-neutrophil aggregation in venules of TNF-α-or hypoxia/reoxygenationchallenged Berkeley (SCD) mice. Importantly, compared with HU or Akti XII treatment alone, short-term treatment with both agents significantly improved survival in those mice. We found that the level of plasma nitric oxide species was elevated by HU but not Akti XII, AKT2 phosphorylation levels in activated neutrophils and platelets were reduced by Akti XII but not HU, and the expression of endothelial E-selectin and intercellular adhesion molecule 1 was decreased by either agent. Our results suggest that short-term co-administration of HU and Akti XII has immediate benefits for acute vaso-occlusive events and survival in SCD mice exceeding those seen for single therapy.
INTRODUCTION
Sickle cell disease (SCD), an inherited blood disorder, results from a homozygous mutation at the 6 th position (Glu6Val) of the β-globin chain (hemoglobin S, HbS) or from compound heterozygous forms like HbSC and HbS-β-thalassemia. 1 HbS tends to polymerize in the deoxygenated state, and this leads to the sickling and hemolysis of red blood cells. 2, 3 Importantly, decreased nitric oxide (NO) bioavailability and increased oxidative stress contribute to the pathophysiology of SCD, including activation of endothelial cells (ECs), inflammation, and organ damage. 4 Recurrent vaso-occlusive events, the hallmark of SCD, are mediated by adhesion and aggregation of red blood cells, leukocytes, and platelets on activated ECs 5, 6 and cause pain crises in SCD patients. 7 Hydroxyurea (HU), the only FDA-approved drug for treatment of SCD, stimulates HbF production, 8 serves as an NO donor, 9, 10 and inhibits tissue factor expression in leukocytes. 11 Although the mechanism by which HU acts is still not fully understood, previous studies showed that treatment of SCD patients with HU is associated with the production of NO and increases HbF levels in a NO-dependent manner. 9, 10 Consistently, studies using a humanized SCD (Berkeley) mouse model revealed that short-term treatment with HU can have immediate benefits on vasoocclusive events, independently of HbF production. 12 The authors further demonstrated that combination therapy of HU and a phosphodiesterase 9 inhibitor efficiently inhibit acute vaso-occlusion in SCD mice. 12 Intravital microscopic studies showed that neutrophil-platelet interactions on activated ECs are the major determinant of vascular occlusion during thromboinflammatory disease in which inflammation is coupled to thrombosis. 5, 13, 14 Although the mechanisms mediating neutrophil-platelet interactions remain poorly understood, previous studies showed that platelet and neutrophil AKT2 play critical roles in regulating platelet P-selectin exposure and activation of β2 integrins, 5,15 thereby mediating neutrophil-EC and neutrophil-platelet interactions under inflammatory conditions. Importantly, we found that basal levels of AKT phosphorylation are significantly increased in neutrophils and platelets isolated from SCD patients compared with healthy donors and that short-term treatment with Akti XII, an AKT2 specific inhibitor, reduces neutrophil adhesion and platelet-neutrophil aggregation in venules of Berkeley mice, resulting in improved blood flow rates. 5 Despite high homology (80%) in protein sequences of the three isoforms, our recent studies clearly indicated that AKT2
could be a dominant isoform regulating heterotypic cell-cell interactions and microvascular occlusion under inflammatory conditions.
In the present study, we investigated whether short-term co-administration of HU and Akti XII has beneficial effects on acute vaso-occlusive events and survival in Berkeley mice challenged with TNF-α or hypoxia/reoxygenation.
MATERIALS AND METHODS
For a full description of all methods, see Supplemental Methods. Intravital microscopy and survival times. Berkeley mice were injected via a tail vein with saline or HU, 100 µg/g body weight (BW) and subsequently treated with intraperitoneal injection of TNF-α (500 ng), 3 hours prior to imaging. In other experiments, Berkeley mice were placed into an 8% O 2 chamber for 3 hours to induce hypoxia, followed by 3 hours of reoxygenation in room air. The mice were treated with vehicle or HU (100 µg/g BW) at the beginning of reoxygenation via tail vein injection.
Akti XII was administered through a jugular vein right before infusion of Dylight 488-conjugated anti-CD42c (platelet glycoprotein Ibβ) and Alexa Fluor 647-conjugated antiGr-1 (Ly-6G/Ly-6C) antibodies. Images were recorded and analyzed as described in Supplemental Methods. During or after intravital microscopic studies, survival times for each mouse were measured. Each time point began at TNF-α injection ( Figure 1A ) or reoxygenation ( Figure S1A ) and ended when the mouse died or at 6 hours after TNF-α injection or reoxygenation. It was reported that treatment with HU at 100 µg/g BW partially inhibits neutrophil adhesion to the venules of TNF-α-challenged Berkeley mice. 12 We recently demonstrated that platelets and neutrophils isolated from mice treated with 10 µg/g BW of Akti XII showed reduced phosphorylation of AKT2, but not AKT1 and AKT3, ex vivo and that 10 µg/g BW of Akti XII markedly decreased neutrophil adhesion and plateletneutrophil aggregation in TNF-α-challenged Berkeley mice. 5 Using a lower dose of Akti XII (3 µg/g BW), we performed intravital microscopy to determine the combined effect of co-administration of HU and Akti XII on vaso-occlusive events in Berkeley mice. The mice were treated with iv injection of a single dose of HU (100 µg/g BW) prior to ip injection of TNF-α ( Figure 1A ). Surgical procedures were carried out at 2.5 hours after further decreased neutrophil adhesion to ECs. As determined by the fluorescence intensities of anti-CD42c antibodies, HU-or Akti XII-treated Berkeley mice exhibited no effect on platelet-neutrophil interactions ( Figure 1E ). In contrast, the mice treated with both agents showed a near complete inhibition of platelet-neutrophil interactions. These results suggest that co-administration of HU and Akti XII efficiently inhibits vasoocclusive events in TNF-α-challenged Berkeley mice.
Statistics
Intraperitoneal injection of TNF-α into Berkeley mice and subsequent surgical trauma lead to death within several hours of TNF-α injection as a result of acute vaso-occlusive events. 12, 16 We found that compared to the vehicle control, treatment with HU alone offered no increased survival, whereas treatment with Akti XII (3 µg/g BW) improved survival in the Berkeley mice ( Figure 1F ). Fifty percent of mice died at 3.6, 3.9, 4.8, and
5.2 hours after TNF-α injection in vehicle-, HU-, Akti XII-, and both HU-and Akti XIItreated mice, respectively (P = 0.0012 between HU and HU + Akti XII and P = 0.031 between Akti XII (3 μg/g BW) and HU + Akti XII). Most mice treated with 10 µg/g BW of Akti XII survived 6 hours after TNF-α injection, supporting our recent findings that AKT2 could be a novel target for treatment of thromboinflammatory disease.
Combination therapy efficiently inhibits neutrophil transmigration into the lung alveoli in TNF-α-challenged Berkeley mice
It was reported that increased vascular permeability may cause acute inflammation in the lung of Berkeley mice. 17 Thus, we performed histochemistry to measure neutrophil transmigration into the alveoli. The number of transmigrated neutrophils was decreased in HU-or Akti XII-treated Berkeley mice, compared with the vehicle control ( Figure 1G -H). Co-administration of HU and Akti XII further diminished neutrophil transmigration, suggesting that combination therapy has beneficial effects on pulmonary inflammation in TNF-α-challenged Berkeley mice, which may explain the improved survival after short-term treatment.
Co-administration of HU and Akti XII has beneficial effects on heterotypic cell-cell interactions and markedly improves survival in hypoxia/reoxygenationchallenged Berkeley mice
Previous studies showed that platelet-neutrophil aggregation is induced in blood isolated from Berkeley mice challenged with hypoxia (8% oxygen for 3 hours) and subsequent reoxygenation (room air for another 3 hours). 18 Using this hypoxia/reoxygenation model, the same intravital microscopy was performed.
Compared with TNF-α-challenge, hypoxia/reoxygenation challenge showed increased rolling and decreased adhesion of neutrophils in venules of Berkeley mice (Figure S1B-D). Platelets adhered to neutrophils as a single cell and did not form thrombi ( Figure   S1E ). The vehicle-treated mice died within 4.2 hours after reoxygenation (1.2 hours after surgery, Figure S1F ). However, very few neutrophils transmigrated into the lung alveoli of hypoxia/reoxygenation-challenged Berkeley mice (data not shown). Compared with HU or Akti XII alone, co-administration of HU and Akti XII showed a significant increase in the rolling influx ( Figure S1C ). Strikingly, all mice treated with both agents survived until the end of the experiment (6 hours after reoxygenation, Figure S1F ).
Although the mechanisms mediating hypoxia/reoxygenation-induced death of Berkeley mice may be different from those in TNF-α-challenged mice, our results suggest that coadministration of HU and Akti XII has beneficial effects on vaso-occlusive events and survival in hypoxia/reoxygenation-challenged Berkeley mice.
The expression of E-selectin and ICAM-1 is affected by treatment with HU or Akti XII EC E-selectin and ICAM-1 are critical for neutrophil rolling and adhesion, respectively, during vascular inflammation. 19 To determine the effect of HU and/or Akti XII treatment on the expression of those proteins, we performed immunohistochemistry using cremaster muscles taken from the mice after intravital microscopy. The expression of E-selectin and ICAM-1 was significantly decreased by HU or Akti XII treatment, compared to the vehicle control (Figure 2A-D) . E-selectin expression was further reduced in the mice treated with both HU and Akti XII, whereas no further reduction of ICAM-1 expression was observed. Since co-administration of HU and Akti XII is more beneficial than single treatment in inhibiting cell-cell interactions and survival in TNF-α-challenged Berkeley mice, these results suggest that the function of blood cells, such as neutrophils and platelets, is also impaired by both agents.
The level of plasma NO metabolites is affected by short-term treatment with HU
Previous studies showed that the effect of oral administration of HU on the level of plasma NO metabolites could be different dependent on SCD patients. 10 Thus, we further measured the level of plasma nitrites and nitrates (NOx) in Berkeley mice after intravital microscopy. Blood was drawn immediately after the mice died or at the end of the experiment. We found that plasma NOx levels were increased by 2.4-or 2.1-fold in mice treated with HU alone or both HU and Akti XII, respectively, compared to the vehicle control ( Figure 2E ). There was no difference between HU and double-treated groups. Treatment with Akti XII did not influence plasma NOx levels. Similar results were also obtained in hypoxia/reoxygenation-challenged Berkeley mice ( Figure S1G ) in which the levels of circulating NOx were relatively higher than those in TNF-α-challenged Berkeley mice. In controls, treatment of WT (C57BL/6) and Hbb +/-(hemizygous) mice with HU alone significantly increased plasma NOx levels ( Figure   S2 ), suggesting that iv injection of HU (100 µg/g BW) serves as a NO donor in mice.
The level of cellular NO inhibits ICAM-1 expression in activated ECs
Because most actions of NO are intracellular and NO donors are known to inhibit ICAM-1 expression in activated ECs, 20 we determined whether sodium nitroprusside (SNP), a well-known NO donor, 21 affects ICAM-1 expression in TNF-α-activated ECs.
Due to technical difficulties in isolating mouse vascular ECs, human umbilical vein ECs (HUVECs) were used in this study. Immunoblotting analysis showed that SNP treatment during TNF-α stimulation dose-dependently decreased ICAM-1 expression in HUVECs ( Figure S3A -B). Complete inhibition was observed when HUVECs were stimulated with TNF-α in the presence of 10 μM SNP. These results support our speculation that NO produced by short-term treatment with HU may inhibit ICAM-1 expression in TNF-α-activated cremaster muscle ECs.
Treatment with Akti XII or both HU and Akti XII reduces the phosphorylation levels of neutrophil and platelet AKT2 ex vivo
We reported that AKT2 phosphorylation is significantly reduced in platelets and neutrophils isolated from WT mice treated with 10 μg/g BW of Akti XII. 5 To further examine whether HU and a low concentration of Akti XII (3 μg/g BW) affect AKT2 phosphorylation in neutrophils and platelets ex vivo, Berkeley mice were treated with HU and Akti XII at 3 and 0.5 hours, respectively, prior to cell isolation. We found that the phosphorylation level of AKT2, but not AKT1, was significantly decreased in fMLFstimulated neutrophils ( Figure 2F -G) and thrombin-activated platelets ( Figure 2H-I) isolated from the mice that received Akti XII alone or both HU and Akti XII, compared to the cells isolated from vehicle-or HU-treated mice. There was no difference between Akti XII and double-treated groups.
Using platelets and neutrophils isolated from Berkeley mice, we further examined whether SNP affects AKT2 phosphorylation during cell activation. We observed that SNP treatment at a concentration of 10-100 μM showed different effects on AKT2 phosphorylation in platelets and neutrophils; inhibition of AKT2 phosphorylation in thrombin-activated platelets, but enhancement of AKT2 phosphorylation in fMLFstimulated neutrophils ( Figure S3C-F) . These results imply that dependent on the cellular level, NO may differentially regulate AKT2 phosphorylation in activated platelets and neutrophils. We found that treatment with 100 μM SNP significantly increased the cellular NOx levels in isolated platelets or neutrophils ( Figure S3G-H) . Pretreatment of platelets with 10-100 μM SNP, compared to vehicle or 1 μM SNP, elevated cellular NOx levels in a concentration-dependent manner following thrombin stimulation, whereas only the highest concentration (100 μM) of SNP increased the NOx levels in fMLFstimulated neutrophils. Interestingly, platelet and neutrophil activation affected cellular NOx levels differently after pretreatment with 100 μM SNP; platelet activation significantly increased NOx levels, but neutrophil activation markedly decreased it. This may result from a large amount of reactive oxygen species produced from activated neutrophils which can disrupt NO homeostasis.
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DISCUSSION
Previous studies suggested that increased oxidative stress consumes NO, decreasing NO levels in Berkeley mice and that decreased NO bioavailability aggravates oxidative stress in SCD patients. 23, 24 It was reported that HU-induced HbF production is mediated by activation of soluble guanylyl cyclase in a NO-dependent manner. 9 Consistently, transgenic Berkeley mice expressing increased levels of HbF exhibited a significant increase in the level of NO metabolites. 23 Recent studies showed that the beneficial effects of iv injection of HU (100 μg/g BW) in TNF-α-challenged Berkeley mice was abolished when co-administered with a NO scavenger, 12 suggesting that short-term treatment with HU serves as a NO donor. However, it is unclear whether such a high dose of HU can be used for iv injection in SCD patients because of the potential toxicity and whether short-term treatment of SCD patients with HU increases circulating NO levels. In the present study, we found that compared to the vehicle control, HU treatment significantly increased plasma NOx levels in Berkeley mice, which is likely to reduce oxidative stress. Further, our ex vivo immunofluorescence microscopy showed that NO produced by HU treatment might inhibit ICAM-1 expression in TNF-α-activated cremaster ECs, which was supported by our in vitro studies using SNP-treated In addition to HU, numerous inhibitors have been tested in SCD mice and patients to reduce vaso-occlusive events. Some novel agents that are currently in clinical trials induce HbF production (Decitabine and HQK-1001), 26, 27 inhibit the activation and adhesive function of neutrophils (GMI-1070) 28 and platelets (Prasugrel) 29 , impair blood coagulation (Tinzaparin), 30 and decrease oxidative stress (Omega-3 fatty acids and Nacetyl cysteine). 31, 32 In particular, the randomized phase II study with GMI-1070
(Rivipansel), a pan selectin inhibitor, has shown that when given to SCD patients early in the hospitalization for treatment of vaso-occlusive events, it reduces requirement for parenteral opioid analgesia and displays a trend to decrease time to resolution as indicated by readiness for discharge from hospital. 28 Previous studies demonstrated that inhibition or deletion of AKT2 significantly decrease neutrophil and platelet activation, thereby reducing neutrophil-EC and platelet-neutrophil interactions and improving blood flow rates during vascular inflammation. 5, 15 Furthermore, the present study reveals that co-administration of HU and Akti XII has beneficial effects on acute vaso-occlusive events and survival in TNF-α-or hypoxia/reoxygenation-challenged Berkeley mice.
Because of the enrichment in insulin-responsive tissues, AKT2 is required to maintain normal glucose homeostasis. 33 We found that one infusion of Akti XII at 10-30 μg/g BW into mice inhibited phosphorylation of AKT2, but not AKT1 and AKT3, in activated platelets and neutrophils 5 and does not affect glucose tolerance ( Figure S4 ). Although future studies are necessary to assess the potential toxicity of targeting AKT2, our results provide important evidence that an AKT2 specific inhibitor may be a short-term supplemental therapy for immediate benefits on acute vaso-occlusive events and survival in SCD patients. with saline, HU, Akti XII, or both agents as described in Methods. Neutrophils and platelets were isolated and stimulated with fMLF (N-formyl-methionyl-leucylphenylalanine) and thrombin, respectively. Immunoblotting was performed using equal amounts of protein (50 μg), followed by densitometry using Image J. Representative blots (F and H) and quantitation of AKT2 phosphorylation after normalization to total AKT expression in neutrophils (G) and platelets (I). Data represent the mean ± SEM (n
